Introduction

Vaccines are one of the great success stories of modern medicine and an increasingly important strategy in the fight against antimicrobial resistance. Glycoconjugate vaccines, consisting of a protein component covalently linked to a glycan antigen, are extremely efficacious in preventing infectious disease. However, glycoconjugates have yet to reach their full potential, with currently licensed glycoconjugate vaccines available against only four pathogens. Protein glycan coupling technology, where glycoconjugates are biologically produced in purpose engineered bacterial cells, has the potential to revolutionize the field by lowering manufacturing cost and increasing flexibility for tailor-made vaccines.

Areas covered

This review gives an overview of the past 20 years of PGCT research, discusses the key developments and current status of the technology, and speculates on the future of PGCT-based vaccinology.

Expert opinion

PCGT has the potential to overcome some of the limitations of chemical conjugation production methods. The technology has undergone significant development since its inception, and new discoveries are continually driving the field forward. Vaccines currently in clinical trials have demonstrated the potential of the PGCT to deliver effective glycoconjugate vaccines for unmet medical needs.

中文翻译：

---

改进用于糖缀合物疫苗生产的蛋白质聚糖偶联技术（PGCT）。

介绍

疫苗是现代医学成功的典范之一，也是对抗抗菌素耐药性日益重要的策略。由共价连接至聚糖抗原的蛋白质成分组成的糖缀合物疫苗在预防传染病方面极为有效。但是，糖缀合物尚未发挥其全部潜力，目前仅针对四种病原体提供了当前许可的糖缀合物疫苗。蛋白聚糖偶联技术可以在特定目的的细菌细胞中以生物方式产生糖结合物，它有可能通过降低制造成本和提高定制疫苗的灵活性来彻底改变该领域。

覆盖区域

这篇综述概述了PGCT过去20年的研究，讨论了该技术的关键发展和当前状况，并推测了基于PGCT的疫苗学的未来。

专家意见

PCGT有潜力克服化学共轭生产方法的某些局限性。自从这项技术问世以来，它已经经历了重大的发展，并且新发现不断推动着该领域的发展。目前在临床试验中的疫苗已证明PGCT有潜力提供有效的糖缀合物疫苗，以满足未满足的医疗需求。